LHRH analogue used in breast cancer –
**Core Concept**
The use of LHRH (Luteinizing Hormone-Releasing Hormone) analogues in breast cancer is based on the principle of **hormonal therapy**, aiming to reduce estrogen levels which can fuel the growth of hormone receptor-positive breast cancer cells. This approach is particularly useful in premenopausal women. LHRH analogues work by initially stimulating, then downregulating **GnRH receptors** in the pituitary gland.
**Why the Correct Answer is Right**
Although the specific LHRH analogue is not provided, the mechanism involves initial **agonist** activity, leading to an increase in **LH and FSH** release, followed by **downregulation** of GnRH receptors, resulting in decreased secretion of **LH and FSH**, and consequently, a decrease in **estrogen** production. This reduction in estrogen levels helps in managing hormone receptor-positive breast cancer.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific details, it's challenging to pinpoint why each option might be incorrect, but generally, incorrect options might include drugs that are not LHRH analogues or are used for different indications.
**Option B:** Similarly, without specifics, we can say that an incorrect option would not effectively reduce estrogen levels or is not used in the context of breast cancer treatment.
**Option C:** An incorrect choice might be a drug used for a different purpose or not an LHRH analogue.
**Option D:** This would be another incorrect choice, possibly a drug not related to hormonal therapy in breast cancer.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that LHRH analogues are used to induce **chemical castration**, significantly reducing estrogen production, which is beneficial in the treatment of hormone-sensitive breast cancer, especially in premenopausal women.
**Correct Answer:** D. Leuprolide